The DSG2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population that disrupts the DSG2 gene in the A-549 human lung adenocarcinoma cell line. This loss-of-function model targets Desmoglein-2, a critical desmosomal cadherin, enabling investigation of intercellular adhesion and associated signaling pathways. The polyclonal format offers a heterogeneous pool of gene-disrupted cells, avoiding clonal selection artifacts and providing a robust platform for functional analyses.
The host A-549 cell line is derived from human lung carcinoma tissue and carries a KRAS G12S mutation, making it a widely employed model for alveolar epithelial cell studies, lung adenocarcinoma research, and drug metabolism investigations. Its epithelial character and expression of desmosomal components render it particularly suitable for dissecting the biological roles of DSG2 within a malignant context, where oncogenic KRAS signaling intersects with cell adhesion mechanisms to regulate tumor progression.
DSG2 is an essential component of desmosomes, mediating strong, calcium-dependent cell-cell adhesion via homophilic and heterophilic interactions with Desmocollin 2. Intracellularly, it recruits Plakoglobin and Plakophilin 2, which anchor to Desmoplakin and the intermediate filament network, mainly cytokeratins. DSG2 transcription and activity are controlled by upstream regulators including AP-1, ??-catenin/TCF, EGFR, and TGF-??. Its knockout disrupts desmosome integrity, releasing Plakoglobin to modulate ??-catenin signaling and downstream TCF/LEF-mediated transcription, influencing cell cycle regulators. This perturbs the adhesion-migration balance and can promote epithelial-mesenchymal transition (EMT), linking DSG2 loss to enhanced invasiveness.
In the A-549 model, DSG2 ablation impairs cell-cell cohesion, potentially unleashing migratory and invasive programs while concurrently altering Wnt/??-catenin and EGFR pathway outputs. This system permits detailed analysis of how desmosomal deficiency synergizes with oncogenic KRAS to drive metastatic dissemination. Beyond oncology, the model offers a unique epithelial platform to explore desmosomal dysfunction reminiscent of arrhythmogenic right ventricular cardiomyopathy, albeit in a non-cardiac lineage, thereby expanding the scope of desmosomal research.
Researchers can validate DSG2 disruption via Western blotting and RT-qPCR, visualize desmosomal protein distribution by immunofluorescence, and assess complex formation with Plakoglobin by co-immunoprecipitation. Functional assays include cell adhesion, migration, and invasion tests, as well as ??-catenin/TCF reporter assays to gauge Wnt signaling activity. Barrier integrity can be measured through transepithelial electrical resistance (TEER), and the cells are suitable for screening compounds that target desmosomal or associated pathways. This versatile tool supports investigations into lung cancer cell biology, EMT mechanisms, and therapeutic discovery. For additional technical specifications, please contact Ascent Research.
